Two out of three people having a first heart attack were not on a statin
Table of Contents
1.0 Summary
Researchers reviewed the charts of patients hospitalized with a heart attack between March 2018 and August 2022 and asked two simple questions: what was their cholesterol, and what were they taking for it. Among the 1,159 whose heart attack was their first diagnosed cardiovascular disease, only 33.6% had been on a statin, although 89.0% of the untreated ones already met the eligibility criteria in the 2026 US guideline. Nearly all of them, 94.7%, arrived with an LDL of 55 mg/dL or higher. The gap did not close on the way out either. Among patients who already knew they had cardiovascular disease and still had an LDL of 55 or above, 47.0% were discharged with no change at all to their lipid medication. This is a retrospective chart review, so it cannot say who had tried a statin before and stopped.
2.0 Key Points
- Of 1,159 patients whose heart attack was their first cardiovascular diagnosis, 33.6% were taking a statin beforehand and 94.7% presented with LDL of 55 mg/dL or higher.
- Among those on no lipid-lowering therapy with risk data available, 89.0% already qualified for a statin under the 2026 US dyslipidemia guideline.
- Of 689 patients with previously known cardiovascular disease, 73.7% were on a statin and 3.9% were on combination therapy, yet 81.0% still presented with LDL of 55 mg/dL or higher.
- 94.0% of all patients were discharged on a statin and 81.8% on a high-intensity one, but only 5.0% left on combination therapy.
- Among patients with known disease and LDL of 55 mg/dL or higher, 24.9% had their statin intensified, 7.2% received combination therapy, and 47.0% received no intensification.
3.0 What the study found
Two thirds of the people whose heart attack was their first cardiovascular event had never been on a statin, and by the guideline in force, nearly nine in ten of them should have been offered one [1].
That is a prevention failure, and it is the easier of the two failures to explain. These patients had no diagnosis yet. Someone would have had to calculate their risk, raise the subject, and start a drug for a disease that had not announced itself. Plenty of things get in the way of that conversation.
The second finding is harder to excuse. Among the 689 patients who already carried a cardiovascular diagnosis, 73.7% were on a statin, and 81.0% still walked into the hospital with an LDL of 55 mg/dL or higher [1]. Being on treatment and being treated to target turn out to be different things, and only 3.9% of that group were on any combination therapy.
4.0 The discharge number
A hospital admission for a heart attack is the one moment when a patient is paying complete attention and a physician has undisputed authority to change the medication. The study looked at what happened in that window.
The statin part went well: 94.0% of all patients were discharged on a statin and 81.8% on a high-intensity one [1]. Anything beyond a statin mostly did not happen, and only 5.0% went home on combination therapy.
Narrow that to the group where the case is strongest, patients with known cardiovascular disease whose LDL was 55 mg/dL or higher on admission, and the picture is this: 24.9% had the statin dose raised, 7.2% got a second drug, and 47.0% had nothing changed [1]. Roughly half of the people most obviously undertreated left the hospital on the same regimen that had failed them.
The fix is not complicated, and it is a matter of habit rather than evidence. Check the admission LDL against a target before writing the discharge orders, and add the second agent then rather than deferring it to a follow-up visit that may not happen. /clinical/05-treatment-pathways.html sets out the escalation, and /clinical/12-follow-up-protocol.html covers what has to happen afterward.
5.0 What it cannot tell you
This is a retrospective review of records from one health system over roughly four and a half years, and its limits follow from that [1].
It cannot distinguish a patient who was never offered a statin from one who took a statin, developed muscle symptoms, and stopped. Statin intolerance is a real reason for an untreated patient to be untreated, and the abstract does not record it. Documented contraindications are missing for the same reason. See /clinical/08-statin-intolerance.html for how that group should be handled.
It also stops at the hospital door. Nothing here says whether the patients discharged without intensification had their therapy adjusted a month later in the office, which would soften the discharge finding without erasing it.
What survives those caveats is the admission data, since an LDL drawn on arrival and a medication list are about as hard as observational data gets. Nearly all first heart attacks in this cohort arrived with an LDL above 55 mg/dL, and most of those patients qualified for treatment they were not getting [1].
This summary is provided for clinical decision support only and does not replace individualized clinical judgment. Findings are summarized from the cited primary sources; consult those sources before changing practice.
Version History
| Version | Date | Description |
|---|---|---|
| 1.0.0 | 2026-08-20 | Initial release |
References
- Essa M et al. Lipid Profiles and Lipid-Lowering Therapy at the Time of Acute Myocardial Infarction. JACC. Advances. 2026-08-14. doi:10.1016/j.jacadv.2026.103129. Available at: https://doi.org/10.1016/j.jacadv.2026.103129